NST changes name; takes $13.3m
This article was originally published in Clinica
Molecular imaging and drug development company NST NeuroSurvival Technologies has completed a $13.3m financing round, bringing the total investment received to $40m. The funds, provided by a group of existing shareholders, will be used to support phase III clinical trials of the company's ML-10 compound used for molecular imaging of apoptosis (programmed cell death). In conjunction with the financing, the Petach-Tikva, Israel-based firm has changed its name to Aposense to better reflect its focus on apoptosis-targeting technology.